Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
Francesco Schettini(Target (United States)), Daniele Generali(University of Trieste), Giuseppe Curigliano(European Institute of Oncology), Peter A. van Dam(University of Antwerp), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Nadia Harbeck(Breast Center), Ida Paris(Agostino Gemelli University Polyclinic), Giorgio Mustacchi(University of Trieste), Diana Lüftner(Beiersdorf (Germany)), Sergio Venturini(University of Turin), Rupert Bartsch(Universitätszahnklinik Wien), Sylvie Rottey(Ghent University Hospital), Alessandra Gennari(Ente Ospedaliero Ospedali Galliera), Khalil Zaman, Concetta Elisa Onesti, Javier Cortés(Villa Maria Hospital), Hans Wildiers(KU Leuven), Vivianne C. G. Tjan‐Heijnen(Maastricht University Medical Centre), Mario Giuliano(Regione Campania), Mario Campone(Institut de Cancérologie de l'Ouest), Guy Jérusalem(Centre Hospitalier Universitaire de Liège), Joseph Gligorov(Sorbonne Université), Lucia Del Mastro(Ospedale Policlinico San Martino), Sabino De Placido, Matteo Lambertini(Ospedale Policlinico San Martino), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Miguel Martín(Hospital General Universitario Gregorio Marañón), Mariavittoria Locci
Cited by 19
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Breast cancer
|The Lancet|2016|2.3k